Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Agenus Inc.

Market Cap 141M 122M 112M 105M 197M 13.42B 200M 1.33B 517M 6.53B 530M 519M 22.61B P/E Ratio 2026 *
4.32x
P/E Ratio 2027 * -2.73x
Enterprise Value 141M 122M 112M 105M 197M 13.42B 200M 1.33B 517M 6.53B 530M 519M 22.61B EV / Sales 2026 *
0.76x
EV / Sales 2027 * 1.07x
Free-Float
93.3%
Yield 2026 *
-
Yield 2027 * -
05-21 Agenus Inc Presents Phase 2 Botensilimab Plus Balstilimab Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma CI
05-21 Agenus and Noetik Present Asco 2026 Data Linking Ai Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with Bot+Bal in Mss Metastatic Crc CI
05-15 Agenus Inc Announces Publication Of Phase 1b Botensilimab And Balstilimab Data In Post-Immunotherapy Hepatocellular Carcinoma CI
05-15 Agenus Inc. Announces Resignation of Austin Charette as Principal Accounting Officer, Effective May 29, 2026 CI
05-11 Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-11 Agenus reports first quarter 2026 financial results and highlights BOT+BAL execution across global access and Phase 3 development RE
04-28 Biodlink International Company Limited Announces Changes in Executives and Board Committee, Effective from 29 April 2026 CI
04-21 Agenus Names BAP Pharma as Global Partner for Botensilimab Plus Balstilimab Access Programs MT
04-21 Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 CI
04-21 Agenus Inc Names BAP Pharma As Exclusive Global Partner For Botensilimab Plus Balstilimab Access Programs CI
04-17 Agenus reports phase II data demonstrating immune reprogramming and durable survival with botensilimab, balstilimab and agent-797 in PD-1 refractory gastroesophageal cancer RE
04-17 Agenus Inc Announces Phase II Data For Botensilimab, Balstilimab and AgenT-797 In Pd-1 Refractory Gastroesophageal Cancer CI
04-01 Agenus Inc Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial Of BOT Plus BAL Immunotherapy Combination In MSS Or PMMR Metastatic Colorectal Cancer CI
1 day-0.88%
1 week+3.72%
Current month-4.29%
1 month-2.62%
3 months+12.42%
6 months-11.61%
Current year+6.69%
1 week 3.04
Extreme 3.04
3.45
1 month 3.02
Extreme 3.0201
3.62
Current year 2.71
Extreme 2.71
5.08
1 year 2.71
Extreme 2.71
7.34
3 years 1.38
Extreme 1.38
40.4
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 72 1994-03-30
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 2021-10-31
Director TitleAgeSince
Chairman 72 2010-11-03
Director/Board Member 68 2007-03-07
Director/Board Member 68 2006-12-06
Date Insider Type Main position Quantity % Market Cap.
05-28Free

Chief Executive Officer

4,644 0.0112%
05-14Free

Chief Executive Officer

4,540 0.0118%
04-30Free

Chief Executive Officer

4,233 0.0110%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%+3.72%-30.50%-91.62% 141M
-0.35%+0.97%-15.96%-12.73% 42.96B
+3.23%+2.97%+273.78%+507.11% 31.73B
-0.97%-1.97%+13.01%-15.13% 30.22B
+1.75%-2.19%-4.46%+23.92% 28.94B
+4.09%-1.98%+11.99%+17.37% 23.87B
-1.01%+3.93%+55.30%+116.54% 13.57B
-0.40%-1.29%+6.06%+7.59% 12.96B
+2.30%+4.74% - - 13.39B
-1.00%-2.28%+104.34%+74.84% 12.2B
Average +0.67%-1.10%+45.95%+69.77% 21B
Weighted average by Cap. +0.95%-1.08%+54.17%+95.49%

Financials

2026 *2027 *
Net sales 185M 160M 147M 138M 258M 17.56B 262M 1.74B 677M 8.55B 693M 678M 29.59B 131M 114M 105M 97.93M 184M 12.49B 186M 1.24B 482M 6.08B 493M 483M 21.06B
Net income 46M 39.73M 36.61M 34.27M 64.22M 4.37B 65.22M 432M 169M 2.13B 173M 169M 7.37B -9.9M -8.55M -7.88M -7.38M -13.82M -941M -14.04M -93.04M -36.27M -458M -37.15M -36.36M -1.59B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
26-06-12 3.370 $ -0.59% 261,629
26-06-11 3.390 $ +10.42% 1,214,733
26-06-10 3.070 $ -1.29% 759,000
26-06-09 3.110 $ -0.96% 499,225
26-06-08 3.140 $ -2.79% 367,663
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.390USD
Average target price
15.50USD
Spread / Average Target
+357.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!